Related Experiment Videos
[Clinical evaluation of cefotetan in pediatrics]
Insights
Cefotetan (CTT), a novel cephamycin antibiotic, demonstrated a 68.8% efficacy rate in treating moderate to severe pediatric infections. CTT was well-tolerated, with minimal adverse effects observed in the study population.
Area of Science:
- Infectious Diseases
- Pharmacology
- Pediatrics
Context:
- Cefotetan (CTT) is a new cephamycin antibiotic.
- Pediatric patients aged 1 year 1 month to 9 years with moderate or severe infections were included.
- The study evaluated CTT's efficacy and safety in a pediatric population.
Purpose:
- To assess the clinical efficacy and safety of Cefotetan (CTT) in pediatric patients.
- To determine the effectiveness of CTT against various bacterial infections in children.
- To identify any adverse effects associated with CTT administration in pediatric patients.
Summary:
- Twenty-one pediatric patients received intravenous CTT at daily doses of 26.5 to 120 mg/kg for 2 to 14 days.
- Clinical efficacy was evaluated in 16 patients, with a good response in 11 (68.8%), fair in 1, and poor in 4.
- Pathogen eradication was observed for H. influenzae and K. pneumoniae, while S. faecalis persisted; one case of eosinophilia was noted as the only adverse effect.
Impact:
- Cefotetan (CTT) shows significant potential as an effective antibiotic for treating serious infections in pediatric patients.
- The favorable safety profile suggests CTT can be a valuable therapeutic option in pediatric infectious disease management.
- Further research may explore CTT's role in combating specific resistant bacterial strains in children.
Abstract:
Cefotetan (CTT), a new cephamycin antibiotic, was administered to 21 pediatric patients, 1 year and 1 month to 9 years of age, with moderate or severe infections. CTT was intravenously administered 3 times a day at daily doses of 26.5 to 120 mg/kg for 2 to 14 days, and 0.75 to 31.0 g of the drug were totally given. Total of 21 cases, 12 cases of respiratory tract infections (each 1 case of acute pharyngitis, acute tonsillitis and asthmatic bronchitis, 6 cases of acute pneumonia, 1 case of lung fibrosis and 2 cases of primary atypical pneumonia), 2 cases of urinary tract infections, 1 case of acute appendicitis, 1 case of perianal abscess, 2 cases of sepsis, 1 case of MCLS, 1 case of ReYE's syndrome and 1 case of meningoencephalitis, were received CTT. Five cases were excluded for the evaluation of clinical efficacy, and good response were obtained in 11 cases (effective rate of 68.8%), fair in 1 and poor in 4. Out of 3 strains of causative organisms isolated before the treatment, H. influenzae and K. pneumoniae were disappeared after the CTT treatment, S. faecalis which was resistant against CTT persisted. Neither adverse effects nor abnormal laboratory findings were observed except 1 case of eosinophilia.